Abstract
We report here the design, development and performance of a novel formulation of liposome- encapsulated glucocorticoids (GCs). A highly efficient (>90%) and stable GC encapsulation was obtained based on a transmembrane calcium acetate gradient driving the active accumulation of an amphipathic weak acid GC pro-drug into the intraliposome aqueous compartment, where it forms a GC-calcium precipitate. We demonstrate fabrication principles that derive from the physicochemical properties of the GC and the liposomal lipids, which play a crucial role in GC release rate and kinetics. These principles allow fabrication of formulations that exhibit either a fast, second-order (t(1/2) ~1 h), or a slow, zero-order release rate (t(1/2) ~ 50 h) kinetics. A high therapeutic efficacy was found in murine models of experimental autoimmune encephalomyelitis (EAE) and hematological malignancies.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Capsules
-
Chemical Phenomena
-
Chemistry, Pharmaceutical / methods*
-
Encephalomyelitis, Autoimmune, Experimental / chemically induced
-
Encephalomyelitis, Autoimmune, Experimental / drug therapy
-
Female
-
Glucocorticoids / administration & dosage*
-
Glucocorticoids / chemistry*
-
Glucocorticoids / pharmacokinetics
-
Glucocorticoids / therapeutic use
-
Humans
-
Hydrophobic and Hydrophilic Interactions
-
Leukemia / drug therapy
-
Liposomes
-
Lymphoma, T-Cell / drug therapy
-
Methylprednisolone Hemisuccinate / administration & dosage
-
Methylprednisolone Hemisuccinate / chemistry
-
Methylprednisolone Hemisuccinate / pharmacokinetics
-
Methylprednisolone Hemisuccinate / therapeutic use
-
Mice
-
Multiple Sclerosis / drug therapy
-
Myelin Proteolipid Protein / adverse effects
-
Nanostructures / chemistry*
-
Solubility
-
Water / chemistry
Substances
-
Capsules
-
Glucocorticoids
-
Liposomes
-
Myelin Proteolipid Protein
-
Water
-
Methylprednisolone Hemisuccinate